Mrs Denise Flowers, RPT in Byron, WY - Physical Therapist

Mrs Denise Flowers, RPT is a Physical Therapist based in Byron, Wyoming. Mrs Denise Flowers is licensed to practice in Wyoming (license number 249) and her current practice location is 240 North Cloud Peak, Byron, Wyoming. She can be reached at her office (for appointments etc.) via phone at (307) 754-2753.

NPI number for Mrs Denise Flowers is 1205957628 and her current mailing address is 7 Llama Dr, Powell, Wyoming. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1205957628.

Contact Information

	Mrs Denise Flowers, RPT
	240 North Cloud Peak, Byron, WY 82412
	(307) 754-2753
	Not Available

Healthcare Provider's Profile

Full Name	Mrs Denise Flowers
Gender	Female
Speciality	Physical Therapist
Location	240 North Cloud Peak, Byron, Wyoming
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1205957628
Provider Enumeration Date: 04/03/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mrs Denise Flowers such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1205957628	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	249 (Wyoming)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Denise Flowers is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Denise Flowers, RPT 7 Llama Dr, Powell, WY 82435-8564 Ph: (307) 754-2753	Mrs Denise Flowers, RPT 240 North Cloud Peak, Byron, WY 82412 Ph: (307) 754-2753

News Archive

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

Novel disease mechanism underlying rheumatoid arthritis

Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women's cable television network, Lifetime Television.

What happens when alcohol-dependent subjects view alcohol associated pictures?

Several studies demonstrated that alcohol-dependent patients show altered responses to alcohol-related cues. It is assumed that the regular association of these cues with the ingestion of alcohol leads to conditioned reactions, motivating reward or relief craving and instigating drug intake.

Rainbow Biosciences signs letter of intent to form new joint venture with n3D

Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.

Mrs Denise Flowers, RPT - Physical Therapist in Byron, WY